Sanofi SNY NASDAQ

Sanofi (SNY) has shown moderate revenue growth over the past 3 years, expanding from $45.4B to $46.7B (average +1%/yr). Net income reached $7.8B, reflecting modest earnings improvement at +2.7%/yr on average. The net profit margin is 16.7%, which is high. The company has maintained profitability in all 4 of the past 4 years, demonstrating a consistent earnings track record. The gross margin is 72.3% (high), with a +2.5pp trend over the period. With a $116B market cap and MOAT composite score of 90/100, the company has a strong competitive position.

Criteria proven by this page:

• GROWTH (45/100, Partial) — growth is present but not consistently above 5% across both metrics
• PAST (100/100, Pass) — proving consistent earnings. Looking at the full 27-year history, the company was profitable in 26 of 27 years — an excellent long-term track record
• INCOME (70/100, Pass) — proves strong profitability and pricing power
• MOAT (90/100, Pass) — strong gross margins and market scale prove a durable competitive advantage

Overall SharesGrow Score: 75/100 with 5/7 criteria passed.